Literature DB >> 12869763

CD46 in meningococcal disease.

Linda Johansson1, Anne Rytkonen, Peter Bergman, Barbara Albiger, Helena Källström, Tomas Hökfelt, Birgitta Agerberth, Roberto Cattaneo, Ann-Beth Jonsson.   

Abstract

The human-specific bacterial pathogen Neisseria meningitidis is a major cause of sepsis and/or meningitis. The pili of N. meningitidis interact with CD46, a human cell-surface protein involved in regulation of complement activation. Transgenic mice expressing human CD46 were susceptible to meningococcal disease, because bacteria crossed the blood-brain barrier in these mice. Development of disease was more efficient with piliated bacteria after intranasal, but not intraperitoneal, challenge of CD46 transgenic mice, suggesting that human CD46 facilitates pilus-dependent interactions at the epithelial mucosa. Hence, the human CD46 transgenic mice model is a potentially useful tool for studying pathogenesis and for vaccine development against meningococcal disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12869763     DOI: 10.1126/science.1086476

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  72 in total

Review 1.  Surface organelles assembled by secretion systems of Gram-negative bacteria: diversity in structure and function.

Authors:  David G Thanassi; James B Bliska; Peter J Christie
Journal:  FEMS Microbiol Rev       Date:  2012-05-24       Impact factor: 16.408

Review 2.  Biofilm formation by the human pathogen Neisseria meningitidis.

Authors:  Martin Lappann; Ulrich Vogel
Journal:  Med Microbiol Immunol       Date:  2010-04-08       Impact factor: 3.402

3.  Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model.

Authors:  Lisa A Lewis; David M Vu; Dan M Granoff; Sanjay Ram
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

Review 4.  T-cell stimulation and regulation: with complements from CD46.

Authors:  Claudia Kemper; James W Verbsky; Jeffrey D Price; John P Atkinson
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

5.  Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons.

Authors:  Shaoheng Ni; Kathrin Bernt; Anuj Gaggar; Zong-Yi Li; Hans-Peter Kiem; André Lieber
Journal:  Hum Gene Ther       Date:  2005-06       Impact factor: 5.695

Review 6.  Sensing gram-negative bacterial lipopolysaccharides: a human disease determinant?

Authors:  Robert S Munford
Journal:  Infect Immun       Date:  2007-12-17       Impact factor: 3.441

Review 7.  Emerging roles and new functions of CD46.

Authors:  M Kathryn Liszewski; Claudia Kemper; Jeffrey D Price; John P Atkinson
Journal:  Springer Semin Immunopathol       Date:  2005-11-11

Review 8.  CD46 in innate and adaptive immunity: an update.

Authors:  J Cardone; G Le Friec; C Kemper
Journal:  Clin Exp Immunol       Date:  2011-04-13       Impact factor: 4.330

9.  Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity.

Authors:  Jo Anne Welsch; Dan Granoff
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

Review 10.  T-cell regulation by CD46 and its relevance in multiple sclerosis.

Authors:  Anne L Astier
Journal:  Immunology       Date:  2008-04-02       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.